Across TCGA pan-cancer cohorts, RIPK4 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RIPK4’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RIPK4 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RIPK4 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

HNSC, LUAD, and PDAC are the cancer types where RIPK4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RIPK4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	−0.255	.024	6	view →
LUAD	All	All	+0.217	.002	5	view →
PDAC	Female	All	+0.864	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RIPK4 RNA expression & survival · all RIPK4 data types